Table 4 Multivariate analysis of variables predicting Disease-free-survival (DFS) in a cohort of 65 patients with GATA2 deficiency and 404 patients without known predisposition syndrome.

From: Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome

 

Relative risk

95 CI

P

Age at HSCT

   

≥12 yrs. vs. <12 yrs.

1.1

[0.7–1.6]

n.s.

GATA2 mutated

   

yes vs. no

0.7

[0.4–1.3]

n.s.

Karyotype

   

Monosomy 7 vs. normal

22

[1.2–3.9]

<0.01

Other vs. normal

1.6

[0.8–3.8]

n.s.

Other vs. monosomy 7

0.7

[0.4-1.3]

n.s.

Most advanced MDS type prior to HSCT

   

MDS-EB vs. RCC

1.9

[1.0–3.4]

0.04

MDS-EBt/ MDR-AML vs. RCC

3.7

[2.2–6.3]

<0.01

MDS-EBt/MDR-AML vs. MDS-EB

2.0

[1.2–3.4]

0.01

  1. CI confidence interval, MDS myelodysplastic syndrome, HSCT hematopoietic stem cell transplantation, MDS-EB MDS with excess blasts, MDS-EBt MDS with excess blasts in transformation, RCC refractory cytopenia of childhood, MDR-AML MDS-related acute myeloid leukemia, yrs years.
Back to article page